Autologous vs heterologous cell replacement strategies for Parkinson disease and other neurologic diseases.
Saved in:
| Title: | Autologous vs heterologous cell replacement strategies for Parkinson disease and other neurologic diseases. |
|---|---|
| Authors: | Emborg ME; Preclinical Parkinson's Research Program, Wisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, WI, United States; Cellular and Molecular Pathology Graduate Program, University of Wisconsin-Madison, Madison, WI, United States; Department of Medical Physics, University of Wisconsin-Madison, Madison, WI, United States. Electronic address: emborg@primate.wisc.edu., Gambardella JC; Preclinical Parkinson's Research Program, Wisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, WI, United States; Cellular and Molecular Pathology Graduate Program, University of Wisconsin-Madison, Madison, WI, United States., Zhang A; Aspen Neuroscience, San Diego, CA, United States., Federoff HJ; Kenai Therapeutics, San Diego, CA, United States; Georgetown University Medical Center, Georgetown, Washington, DC, United States. |
| Source: | Handbook of clinical neurology [Handb Clin Neurol] 2024; Vol. 205, pp. 41-56. |
| Publication Type: | Journal Article; Review |
| Journal Info: | Publisher: Elsevier Country of Publication: Netherlands NLM ID: 0166161 Publication Model: Print Cited Medium: Internet ISSN: 0072-9752 (Print) Linking ISSN: 00729752 NLM ISO Abbreviation: Handb Clin Neurol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
